📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-07 16:51
0 analysed today
FollowTelegram
0
Today
151,433
All-time analysed
43,376
Positive
6,732
Negative
92,513
Neutral
8,744
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
Gujarat Terce Laboratories Approves Q1 FY27 Results; Auditor Issues Unmodified Report
Gujarat Terce Laboratories has approved its unaudited standalone financial results for the quarter ended June 30, 2026. The company, a micro-cap pharmaceutical player with a ₹31 Cr market capitalization, is coming off a profitable FY26 (PAT ₹2.2 Cr) following a loss-making FY25. The statutory auditors, Shah Doshi Patel & Associates LLP, provided an unmodified limited review report, indicating no major accounting discrepancies were found during the review.
Confidence: MEDIUM
What changedThe company has formally approved and released its financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersAs a micro-cap company with a ₹31 Cr market cap, quarterly performance is critical to sustain the turnaround seen in FY26, where OPM stood at 7.9%.
TTM Revenue: ₹47 CrTTM PAT: ₹2 CrMarket Cap: ₹31 CrPromoter Holding: 40.03%Meeting Duration: 1.5 hours
📅 Short termThe stock may experience volatility in the coming days as the market digests the specific revenue and margin figures from the Q1 results.
📈 Long termLimited structural impact; this is a routine quarterly filing for a micro-cap pharmaceutical company.
⚠ Risk flags
- Micro-cap liquidity risk
- Relatively low promoter holding at 40.03%
- Historical volatility in operating margins
Key Highlights
Board approved unaudited standalone financial results for the quarter ended June 30, 2026
Statutory auditors issued an unmodified Limited Review Report for the Q1 period
The board meeting was conducted within a 90-minute window (3:00 PM to 4:30 PM)
Company maintains a low Debt-to-Equity ratio of 0.13 as per latest annual data
👀 What to Watch
Investors should examine the full financial statement to see if the company maintained the positive momentum from FY26, specifically checking if quarterly revenue exceeded the ₹11.4 Cr reported in March 2026.
Gujarat Terce FY26 Revenue at ₹47.47 Cr; Net Profit at ₹2.20 Cr; TYNOL Target ₹10 Cr
Gujarat Terce Laboratories reported a 5% decline in FY26 revenue to ₹47.47 crore, attributed to a strategic exit from low-margin B2B manufacturing and regulatory headwinds affecting the Acolate Plus brand. However, the company achieved a net profit of ₹2.20 crore and reduced long-term debt to near zero, while debtor days improved to under 37. Management is focusing on its branded portfolio, specifically targeting ₹10 crore for the TYNOL brand in FY27, up from ₹5.75 crore in FY26. Promoter skin-in-the-game increased as the MD converted warrants at a premium, raising his stake to 40.03%.
Confidence: HIGH
What changedThe company has transitioned from volume-based B2B manufacturing to a brand-focused model, resulting in a cleaner balance sheet but lower immediate revenue.
Why it mattersThe shift toward branded generics (50 brands, 125 products) is intended to improve long-term margins and reduce debt, though it requires higher field force productivity.
FY26 Revenue: ₹47.47 crFY26 Net Profit: ₹2.20 crTYNOL FY26 Value: ₹5.75 crTYNOL FY27 Target: ₹10 crPromoter Holding: 40.03%Debtor Days: 37
📅 Short termThe stock may see neutral to slightly positive sentiment as the market weighs the revenue dip against the return to profitability and debt reduction.
📈 Long termStructural shift to a branded pharma model could re-rate the business if the company successfully scales its core brands (TYNOL, ACOLATE) and maintains low debt.
⚠ Risk flags
- Regulatory risks regarding fixed-dose combinations (FDC)
- High competition in the branded generics segment
- Concentration risk in pediatric and respiratory categories
Key Highlights
FY26 Revenue stood at ₹47.47 crore, a 5% decline from the previous year due to B2B scale-down.
Net profit returned to ₹2.20 crore with an EBITDA of ₹3.63 crore, representing a 7.66% margin.
Flagship brand TYNOL achieved ₹5.75 crore in FY26, with a 19.3% 5-year CAGR and a ₹10 crore target for FY27.
Promoter holding increased by 3% to 40.03% through warrant conversion at a premium of ₹37.70.
Operational efficiency improved with debtor days falling below 37 days and long-term debt reduced to near zero.
👀 What to Watch
Monitor the company's ability to hit the ₹10 crore revenue target for the TYNOL brand in FY27 and the recovery of the ACOLATE franchise following regulatory changes.
Gujarat Terce FY26 Revenue at ₹47.47 Cr; TYNOL Brand Targets ₹10 Cr for FY27
Gujarat Terce reported a 5% revenue decline to ₹47.47 Cr in FY26, primarily due to a strategic exit from low-margin B2B manufacturing and regulatory impacts on its Acolate Plus brand. The company is pivoting toward its branded portfolio, with flagship brand TYNOL growing 14% to ₹5.75 Cr and management targeting ₹10 Cr for FY27. Operational efficiency remains a highlight with debtor days falling below 37. However, MD compensation rose 46.5% to ₹88.09 Lakhs despite the revenue dip, and the company continues to hold ₹4.39 Cr in non-core assets from its discontinued metal division.
Confidence: HIGH
What changedThe company has consciously scaled down B2B manufacturing to focus on its own brands and faced a regulatory setback in its Acolate Plus variant.
Why it mattersThe shift toward a branded-only model could lead to higher margins and better brand equity, but the current scale remains small with a market cap of only ₹26 Cr.
FY26 Revenue: ₹47.47 CrTYNOL Brand Value: ₹5.75 CrMD Compensation: ₹88.09 LakhsAssets Held for Sale: ₹4.39 CrDebtor Days: under 37
📅 Short termThe stock may see neutral to slightly cautious sentiment due to the revenue decline and significant increase in management pay relative to the company's small profit base.
📈 Long termThe structural shift to a branded pharma model is positive for long-term margins, provided the company can successfully scale its top 5 brands beyond their current levels.
⚠ Risk flags
- Significant increase in MD compensation despite revenue decline
- Regulatory risk in Fixed Dose Combinations (FDC) affecting core brands
- Small-cap liquidity and concentration in a few therapeutic areas
Key Highlights
Revenue for FY26 stood at ₹47.47 Cr, a 5% decline from the previous year due to reduced B2B operations.
Flagship brand TYNOL grew 14% in value to ₹5.75 Cr, maintaining a 19.3% 5-year CAGR.
Distribution network expanded to 385 stockists serving 22,000+ retail outlets across 13 states.
MD Aalap Prajapati's compensation increased by 46.5% to ₹88.09 Lakhs from ₹60.11 Lakhs YoY.
Assets held for sale from the discontinued Metal Division are valued at ₹4.39 Cr as of March 2026.
👀 What to Watch
Monitor the company's ability to hit the ₹10 Cr target for TYNOL in FY27 and observe if the shift from B2B to branded sales improves operating margins (currently 7.9%).
